News
Public · Published
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ will be presented in a poster at the 2026 SNO Annual Meeting in Philadelphia, November 12–15, covering the first ten patients.
Published:
Updated:
What happened
Cerenome, Inc. announced that interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ will be presented in a poster at the 2026 SNO Annual Meeting in Philadelphia, November 12–15, covering the first ten patients.
Confirmed
Global impact / market context
The data cover safety, dosing, and tumor-cell measures in leptomeningeal metastases, a fatal condition with no approved treatments. Positive results could support an FDA-aligned Phase 2 dose randomization study in 2027, a key step toward potential accelerated approval and eventual revenue.
Analyst inference
Cerenome is a CNS oncology company combining diagnostics, therapeutics, and artificial intelligence. For investors, the interim readout is a near-term catalyst that could shape expectations for the 2027 Phase 2 plan and the company's path to a first approved product.
Analyst inference
What to watch
- The poster will report interim safety, dosimetry, CSF tumor cell enumeration (biomarker), and individual treatment course data on the first ten patients from the multidose ReSPECT-LMM study. Confirmed
- Cerenome aims to advance into an FDA-aligned Phase 2 dose randomization study in 2027, which would support potential accelerated approval or a follow-on registrational Phase 3 study. Proposed
- Watch whether the interim safety and biomarker results support repeated REYOBIQ dosing, since that readout could determine the timing and design of the planned 2027 Phase 2 study. Analyst inference